Literature DB >> 2070471

Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography.

T Toyo'oka1, T Yamazaki, T Tanimoto, K Sato, M Sato, M Toyoda, M Ishibashi, K Yoshihira, M Uchiyama.   

Abstract

To identify chemical contaminant(s) associated with eosinophilia-myalgia syndrome (EMS), case and control lots of tryptophan were analyzed by HPLC with both UV and FL detection. Numerous contaminant peaks appeared on the chromatograms and some of them were identified as 5-hydroxytryptophan, indol aldehyde, indol, etc; from the retention time of authentic compounds. Among these, three peaks were significantly associated with case lots. One corresponds to di-tryptophan aminal of aldehyde (peak E). Others are unknown contaminants, UV-5 (FL-7) and UV-28 (FL-36). The structural elucidation and toxicological implication of UV-5 (FL-7) are currently in progress.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2070471     DOI： 10.1248/cpb.39.820

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN： 0009-2363            Impact factor:   1.645


  10 in total

1.  Use of cyclosporin A in the eosinophilia myalgia syndrome.

Authors:  D J Clauw; J A Alloway; P Katz
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

2.  Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.

Authors:  J Adachi; T Mio; Y Ueno; T Naito; A Nishimura; S Fujiwara; K Sumino; Y Tatsuno
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

3.  Accumulation of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in blood and organs of the Lewis rats.

Authors:  J Adachi; M Gomez; C C Smith; E M Sternberg
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

Review 4.  Use of tryptophan in combination with other antidepressant treatments: a review.

Authors:  S N Young
Journal:  J Psychiatry Neurosci       Date:  1991-12       Impact factor: 6.186

5.  Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats.

Authors:  L A Love; J I Rader; L J Crofford; R B Raybourne; M A Principato; S W Page; M W Trucksess; M J Smith; E M Dugan; M L Turner
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

6.  Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome.

Authors:  R H Hill; S P Caudill; R M Philen; S L Bailey; W D Flanders; W J Driskell; M L Kamb; L L Needham; E J Sampson
Journal:  Arch Environ Contam Toxicol       Date:  1993-07       Impact factor: 2.804

7.  Analytical characterization of peptide contaminants of L-tryptophan.

Authors:  E R Barnhart; V L Maggio; L R Alexander; M C Reilly; L T Gelbaum; W E Turner; T K Hine; L L Needham
Journal:  Arch Environ Contam Toxicol       Date:  1996-01       Impact factor: 2.804

8.  1,1'-Ethylidenebis(tryptophan) (Peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant.

Authors:  K A Yamaoka; N Miyasaka; G Inuo; I Saito; J P Kolb; K Fujita; S Kashiwazaki
Journal:  J Clin Immunol       Date:  1994-01       Impact factor: 8.317

9.  Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.

Authors:  J Adachi; T Naito; Y Ueno; Y Ogawa; I Ninomiya; Y Tatsuno
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

Review 10.  Regulatory science of natural products.

Authors:  Yukihiro Goda
Journal:  J Nat Med       Date:  2022-07-23       Impact factor: 3.192
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.